NCT01908712View on ClinicalTrials.gov

Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Alpha-Mannosidosis
Interventions
DRUG

Lamazym

ERT, i.v. infusions weekly

Trial Locations (1)

F-69677

Hôpital Femme Mére Enfant - CHU de Lyon, Bron

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT01908712 - Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients | Biotech Hunter | Biotech Hunter